Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Annual testosterone drug revenue in the United States 2013 and 2018

Annual testosterone drug revenue in the U.S. in 2013 and 2018 (in billion U.S. dollars)

by Statista Research Department, last edited Aug 18, 2014
Annual testosterone drug revenue in the United States 2013 and 2018 This statistic depicts the annual testosterone drug revenue in the United States in 2013 and a projection for 2018, in billion U.S. dollars. In 2013, testosterone drugs generated a revenue of 2.4 billion U.S. dollars.
Testosterone therapy

Testosterone therapy is often used to treat men with hypogonadism, where the body produces too little or no natural testosterone. Testosterone can be used as hormone replacement therapy and can be used to treat low libido in post-menopausal women. This form of therapy has also been reported to improve moods as well as energy. By 2018, annual revenue generated from testosterone drug sales in the United States is expected to reach 3.8 billion U.S. dollars. Testosterone use was among the highest in Canada and the United States as of 2011, with 385.5 monthly doses and 98.5 monthly doses per 1,000 population, respectively.

Transdermal application for testosterone for example, through application by skin patch, has become increasingly common. In Canada, Sweden, and the United States, transdermal testosterone application accounted for 97 percent, 78 percent, and 78 percent, respectively, as of 2011. Testosterone supplements can also be taken as a gel, mouth patch, and through injections or implants.

Individuals that enrolled in testosterone therapy prescription often had a prior prescription of hypertension or hyperlipidemia. As of 2014, 26.8 percent with hypertension and 26.5 percent diagnosed with hyperlipidemia enrolled in testosterone therapy prescription. Testosterone therapy has also been linked to adverse cardiovascular events. In individuals under or equal to 65 years of age, the myocardial infarction among men was at 5.27 per 1,000 per year prior to testosterone prescription. The post-prescription rate of myocardial infarction increased to 11.52 per 1,000 per year as of 2014.
Show more

Annual testosterone drug revenue in the U.S. in 2013 and 2018 (in billion U.S. dollars)

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Health expenditures in the U.S."
  • Global comparison
The most important statistics
  • Overview U.S.
  • Categories
  • Payer
  • Out-of-pocket
  • NHE projections
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: You might find this interesting as well
Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.